{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:15:21Z","timestamp":1775589321518,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"DOI":"10.7759\/cureus.106599","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:40:17Z","timestamp":1775587217000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Hypogammaglobulinemia (IgG) During Efgartigimod Therapy in Neurological Practice: A Real-World Case Series"],"prefix":"10.7759","author":[{"given":"Patricio S","family":"Espinosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Preisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Moti\u00f1o Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"McKenzie B","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles H","family":"Hennekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF","year":"2021","unstructured":"Howard JF, Bril V, Vu T, et al.. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021, 20:526-36.","journal-title":"Lancet Neurol"},{"key":"ref2","article-title":"Phase 3 randomized noninferiority study of subcutaneous versus intravenous efgartigimod in generalized myasthenia gravis (ADAPT-SC)","volume":"21","author":"Howard JF Jr","year":"2024","unstructured":"Howard JF Jr, Vu T, Li G, et al.. Phase 3 randomized noninferiority study of subcutaneous versus intravenous efgartigimod in generalized myasthenia gravis (ADAPT-SC). Eur J Neurol. 2024, 21:e00378.","journal-title":"Eur J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in chronic inflammatory demyelinating polyneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen JA","year":"2024","unstructured":"Allen JA, Lin J, Basta I, et al.. Safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in chronic inflammatory demyelinating polyneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2024, 23:1013-24. 10.1016\/S1474-4422(24)00309-0","journal-title":"Lancet Neurol"},{"key":"ref4","unstructured":"VYVGART (efgartigimod alfa-fcab) injection, for intravenous use. prescribing information. (2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761195s004,761304s003lbl.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard JF Jr","year":"2024","unstructured":"Howard JF Jr, Bril V, Vu T, et al.. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2024, 14:1284444. 10.3389\/fneur.2023.1284444","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.04.003","article-title":"Efgartigimod: potential impact on IVIG therapy","volume":"10","author":"Demain JG","year":"2022","unstructured":"Demain JG, Bonilla FA. Efgartigimod: potential impact on IVIG therapy. J Allergy Clin Immunol Pract. 2022, 10:1930. 10.1016\/j.jaip.2022.04.003","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas MC","year":"2021","unstructured":"Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021, 14:7381. 10.1177\/1756286421997381","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/481883-severe-hypogammaglobulinemia-igg-during-efgartigimod-therapy-in-neurological-practice-a-real-world-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:40:18Z","timestamp":1775587218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/481883-severe-hypogammaglobulinemia-igg-during-efgartigimod-therapy-in-neurological-practice-a-real-world-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.106599","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}